Table 3.
Cramér-Rao Lower Bound estimates for each metabolite (Glx, GABA+) in each voxel Absolute values (and standard deviations).
| Voxel | Drug | Metabolite | TD | ASD | F(dof) | p-value |
|---|---|---|---|---|---|---|
| BG | PLC | GABA+ | 4.56 (0.66) | 4.82 (0.81) | F(1) = 1.095 | 0.303 |
| Glx | 7.50 (2.09) | 7.56 (2.25) | F(1) = 0.007 | 0.935 | ||
| CBDV | GABA+ | 4.38 (0.51) | 4.79 (0.80) | F(1) = 2.371 | 0.136 | |
| Glx | 6.77 (1.36) | 7.21 (2.29) | F(1) = 0.368 | 0.549 | ||
| DMPFC | PLC | GABA+ | 6.47 (0.87) | 7.38 (2.06) | F(1) = 2.751 | 0.107 |
| Glx | 5.68 (0.73) | 5.88 (1.02) | F(1) = 0.416 | 0.524 | ||
| CBDV | GABA+ | 6.50 (0.67) | 7.07 (1.73) | F(1) = 1.153 | 0.294 | |
| Glx | 5.85 (1.14) | 5.57 (0.94) | F(1) = 0.469 | 0.500 |
ASD Autism spectrum disorder, BG Basal ganglia, CBDV Cannabidivarin, CSF Cerebrospinal fluid, DMPFC Dorsomedial prefrontal cortex, F(dof) F-value and degrees of freedom, GABA+ gamma-aminobutyric acid + macromolecules, Glx glutamate + glutamine, PLC Placebo, SD Standard deviation, TD Typically developing controls